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Abstract
Background: The malignant potential of serous ovarian tumors, the most common ovarian tumor
subtype, varies from benign to low malignant potential (LMP) tumors to frankly invasive cancers.
Given the uncertainty about the relationship between these different forms, we compared their
patterns of gene expression.
Methods: Expression profiling was carried out on samples of 7 benign, 7 LMP and 28 invasive
(moderate and poorly differentiated) serous tumors and four whole normal ovaries using
oligonucleotide microarrays representing over 21,000 genes.
Results: We identified 311 transcripts that distinguished invasive from benign tumors, and 20
transcripts that were significantly differentially expressed between invasive and LMP tumors at p <
0.01 (with multiple testing correction). Five genes that were differentially expressed between
invasive and either benign or normal tissues were validated by real time PCR in an independent
panel of 46 serous tumors (4 benign, 7 LMP, 35 invasive). Overexpression of SLPI and WNT7A and
down-regulation of C6orf31, PDGFRA and GLTSCR2 were measured in invasive and LMP compared
with benign and normal tissues. Over-expression of WNT7A in an ovarian cancer cell line led to
increased migration and invasive capacity.
Conclusion: These results highlight several genes that may play an important role across the
spectrum of serous ovarian tumorigenesis.
Background
In Australia, the age-standardized incidence of ovarian
cancer was 11 cases per 100,000 women in 2005, and
approximately 8 deaths per 100,000 women resulted
from this disease in the same time period [1]. The difficul-
ties associated with making improvements in early diag-
nosis of epithelial ovarian cancer partly result from a lack
of knowledge regarding the pathway to tumor develop-
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ment. It is believed that the ovarian surface epithelium
(OSE) is a common site for the initiation of ovarian car-
cinogenesis and most studies have identified genes
involved in ovarian tumorigenesis by comparing gene
expression profiles with normal OSE [2-8]. The major his-
tological subtypes of epithelial ovarian cancer resemble
neoplasms arising from other organs of the female genital
tract that are derived from the Mullerian ducts during
embryogenesis [9]. Thus it has been suggested that the
comparison of Mullerian-appearing ovarian tumors with
a tissue exhibiting mesothelial characteristics (OSE) may
preferentially identify markers of Mullerian differentia-
tion rather than true markers of neoplastic transformation
[10,11].
To identify genes associated with neoplastic progression
in the serous subtype of ovarian tumors, we compared
gene expression in tissues that exhibited the spectrum of
tumor behavior, namely benign, low malignant potential
(LMP) and invasive. Compared with invasive tumors,
benign tumors lack evidence of cellular atypia and are
non-invasive, while LMP tumors display atypical prolifer-
ation but do not usually invade below the basement
membrane of the ovarian surface epithelium [12]. Benign
and LMP tumors usually result in an excellent prognosis
for the patient.
In order to clarify the molecular relationships among the
spectrum of serous ovarian tumors, we compared gene
expression profiles of 7 LMP and 28 invasive (moderate
and poorly differentiated or Grade 2 and Grade 3) serous
ovarian tumors with two different reference groups: 7




Women aged 18-79 with suspected ovarian cancer and
who were being treated at the Royal Brisbane and
Women's Hospital were recruited to the study between
1999 and 2006. Chemotherapy-naïve tissues were col-
lected during surgery and immediately frozen (for RNA
extraction) or fixed in 10% buffered formalin to embed in
paraffin. To ensure a homogeneous dataset in which to
compare tumor behavior, analyses were restricted to
tumors of the serous histological subtype and four normal
whole ovary specimens collected from women having sur-
gery for other benign gynecological conditions. Forty-two
tumors (7 benign cystadenomas/cystadenofibromas, 7
LMP and 28 invasive (moderate and poorly differentiated
or G2 and G3) tumors) and four normal ovarian samples
were initially selected for analysis (Table 1, see Additional
file 1 for detailed information on tissues analyzed by
microarray analysis). A second set of tissues (4 benign, 7
LMP, 35 invasive (G2, G3) serous tumors and one normal
ovary) was used for validation (Table 2, see Additional file
2 for more information on tissues analyzed by real time
PCR). All tumor tissues were independently reviewed by
an experienced pathologist (D.J.P.) to verify histological
subtype and tumor grading and to estimate the percent
epithelial content (Additional file 1). Informed consent
was obtained from all participants and the study protocol
was approved by the Queensland Institute of Medical
Research, Royal Brisbane and Women's Hospital and the
University of Queensland Human Research Ethics Review
Committees. The study was conducted according to the
Declaration of Helsinki Principles.
RNA extraction
RNA was extracted from all tissues for oligonucleotide
microarray analysis (set 1 only) and gene expression
quantitation by real time PCR. Approximately 100 mg of
fresh frozen tumor and normal ovary tissue was used for
extraction following the protocol outlined by Newton et
al. [13]. All RNA was treated with RNase-free DNase
(Roche, Castle Hill, New South Wales, Australia) and only
those samples with 28S:18S ratios  1.7 were selected to
ensure high quality. RNA concentrations were estimated
using the Nanodrop ND-1000 (NanoDrop Technologies
Inc, Wilmington, DE).
Expression profiling
Human Genome v 2.1 microarrays representing 21,329
genes (Qiagen Operon oligo set) were purchased from the
Prostate Centre at the Vancouver General Hospital. Total
Table 1: Tumor grade and stage details of low malignant 
potential and invasive tissues analyzed by microarray 
hybridization
Grade Stage
Total Well1 Mod1 Poor1 I II III IV
Normal 4 - - - - - - -
Benign 7 - - - - - - -
LMP2 7--- 4 1 2 -
Invasive 28 - 6 22 2 4 21 1
1 Well, moderate and poorly differentiated. 2 Low malignant potential.
Table 2: Tumor grade and stage details of low malignant 
potential and invasive tissues analyzed by real time PCR
Grade Stage
Total Well1 Mod1 Poor1 I II III IV
Normal 1 - - - - - - -
Benign 4 - - - - - - -
LMP2 7--- 5 - 2 -
Invasive 35 - 5 30 - - 29 6
1 Well, moderate and poorly differentiated. 2 Low malignant potential.BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
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RNA (20 g) from individual tumor tissues and Universal
Human Reference RNA (Stratagene, La Jolla, CA) was
labeled with Cy5 and Cy3, respectively, using an amino
allyl (indirect) method with the CyScribe Post-Labeling
kit (Amersham Biosciences, Piscataway, NJ) as per the
manufacturer's instructions. Purification of amino allyl-
modified and CyDye-labeled cDNA was achieved using
the CyScribe GFX Purification kit (Amersham Bio-
sciences). For hybridization, test and reference cDNA were
pooled and mixed with 20 g Cot-1 DNA (Invitrogen,
Carlsbad, CA), 20 g of poly dA (Sigma, St. Louis, MO),
40 g of Salmon Testis DNA (Sigma) and 60 l DIG Easy
hybridization solution (Roche). Hybridization mix was
placed on the microarray slide, coverslipped and incu-
bated overnight at 37°C in humidified hybridization
chambers (TeleChem International, Sunnyvale, CA).
Microarrays were washed twice in 1× SSC, 0.1% SDS for 5
min, once in 1× SSC and once in 0.1× SSC for 3 min.
Microarrays were dried by centrifugation at 100 × g for 5
min and immediately scanned using the GMS-418 confo-
cal scanner (Genetic MicroSystems/Affymetrix, Santa
Clara, CA). Images were imported into ImaGene 5 (Bio-
Discovery, Marine Del Rey, CA) for data extraction. Mean
pixel intensities (test to reference) in the Cy5 and Cy3
channels were imported into GeneSpring 7 for analysis
(Agilent/Silicon Genetics, Redwood City, CA). All ele-
ments were reviewed manually and those of poor quality
were removed from subsequent analysis. The data dis-
cussed in this publication have been deposited in the
NCBI Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through
GEO [GEO: GSE17308].
Microarray data normalization and analysis
Fluorescent intensities were normalized to the mean
expression level in each array and for each element (Low-
ess normalization). Data were additionally normalized to
the median for each gene, or expressed relative to the
median fluorescence ratios for a particular gene in all 46
samples. Gene expression data were calculated as the ratio
of the test to reference fluorescent intensity. To eliminate
low quality elements, those with intensities between 50
and 65,000 fluorescent units in the test (signal) channel
in 75% of arrays were selected, resulting in 17,244 genes
for analyses. Unsupervised hierarchical clustering meth-
ods were applied to 3,197 genes exhibiting greatest vari-
ance ( 0.5 SD) across all samples. Clustering trees were
constructed using average linkage algorithms and Pear-
son's correlation. ANOVA analysis was applied to identify
genes that were differentially expressed between all tumor
groups and normal ovaries. Student's t-tests were applied
to pair-wise comparisons between invasive and LMP or
benign tumors. The Benjamini and Hochberg FDR multi-
ple testing correction [14] was applied to all ANOVA anal-
yses and tests were conducted at a significance level of p <
0.01. Thus, using the FDR multiple testing correction it is
estimated that 1 in every 100 genes (1%) will be due to
chance.
Quantitative real time PCR
Primer sets were designed to amplify chromosome 6 open
reading frame 31 (C6orf31; F: 5'-CACACGACTACAT-
GCCCATC-3'; R: 5'-CGGTGAGGATGGTACAGAGC-3'),
glioma tumor suppressor candidate region gene 2
(GLTSCR2; F: 5'-CGGTTCAAGAGCTTCCAGAG-3'; R: 5'-
CTGATGGCAGCTACAACTGG-3'), platelet-derived
growth factor receptor, alpha polypeptide (PDGFRA; F: 5'-
GCGCTGACAGTGGCTACAT-3'; R: 5'-TTCAGAGGTCT-
GCGAGCTG-3'), secretory leukocyte protease inhibitor
(SLPI; F: 5'-GGCTCTGGAAAGTCCTTCAAAGC-3'; R:-5'
CATAAGTCACTGGGCACTT CC-3'), TCF3 (E2A) fusion
partner (TFPT; F:-5' CGGAAGTGGAGTTTGTGTCA-3'; R:
5'-CTCGTTCACCTGCTCGATCT-3') and wingless-type
MMTV integration site family member 7A (WNT7A) [15]
for real time PCR. First strand cDNA was produced from
total RNA as previously described [16]. The reaction
included 5 l of a 1/50 dilution of cDNA, 1× QuantiTect
SYBR Green PCR Master Mix (Qiagen, Clifton Hill, Victo-
ria, Australia), 0.5 M of forward and reverse primers and
3 l of water. PCR reactions were performed using the
Corbett RotorGene 6000 (Corbett Research, Sydney, New
South Wales, Australia). Gene expression levels were nor-
malized using Beta-2-microglobulin (B2M) [13]. Product
quantitation was determined as previously described [17].
Extreme outliers exhibiting expression levels beyond
those expected were noted and removed from statistical
analyses.
Immunohistochemistry
Analysis of formalin-fixed paraffin-embedded sections
from serous tumors and normal ovaries previously ana-
lyzed by microarrays was performed using antibodies
directed against SLPI (NCL-SLPI 1/100 dilution; Novocas-
tra Laboratories Ltd, Newcastle, UK)). The experimental
protocol was adapted from manufacturer's instructions.
Antigen retrieval was performed by autoclaving in 0.01 M
trisodium citrate buffer (pH 6.0) at 105°C. Endogenous
peroxidase activity was blocked with 0.5% hydrogen per-
oxide. Sections were blocked with 10% normal goat
serum (Vector Laboratories, Burlingame, CA) and incu-
bated overnight with primary antibody at 4°C. The DAKO
Envision plus secondary antibodies (DakoCytomation,
Carpinteria, CA) were applied and slides were stained
using AEC+ substrate chromogen and counterstained with
hematoxylin. Scoring was done by the study pathologist
(D.J.P.) who was blinded to the study objectives. The per-
centage of cells staining and intensity of staining in both
epithelial and stromal cells were recorded. Staining posi-
tivity was determined when any positive stain was noted.BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
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Negative controls (no primary antibody added) were car-
ried out to confirm antibody specificity.
Statistical analyses
Correlations between microarray and real time PCR exper-
iments were assessed using Spearman's Rank Correlation.
To assess differences in mRNA and protein expression of
selected genes between the groups, the Kruskal Wallis test
was applied to microarray and real time PCR analyses and
Fisher's Exact test was used to analyze immunohistochem-
istry data. A p-Value < 0.05 was considered statistically sig-
nificant.
WNT7A vector construction and transfection
Full length WNT7A cDNA was amplified by RT-PCR from
a malignant ovarian tumor using the primers 5'
CGCGAATTCACTATGAACCGGAAAGCGCGGCGCT-
GCCTG 3' and 5' GCGACCGGTCTTGCACGTGTA-
CATCTCCGTGCGCTC 3'. PCR products were detected
and then cloned into the EcoRI and AgeI sites of the
pcDNA3.1/V5-His A plasmid (Invitrogen). The PCR prod-
uct was verified by sequencing. OVCAR-3 cells were
seeded at 2 × 105/ml in 60 mm dishes and transfected the
following day with 2 g of plasmid DNA and 8 l of Meta-
fectine (Biontex Laboratories, Munich, Germany) as per
the manufacturer's instructions. As a control, OVCAR-3
cells were transfected with the pcDNA3.1/V5-His A empty
vector. Cells were selected in media containing 400 g/ml
geneticin (G-418; Invitrogen) for 3 weeks, and individual
stable clones were picked for further analysis. Thereafter,
clones were maintained on media containing 300 g/ml
G-418. Increased expression of WNT7A protein was con-
firmed by western blotting of whole cell lysates with Anti-
WNT7A antibody (Q-12, Santa Cruz). Expression of beta
actin served as the loading control.
Cell growth assay
Cells were seeded in triplicate at 5,000 per microtiter well
and allowed to attach. A separate plate was seeded for
each time point at which cells were fixed and growth was
estimated by the intensity of sulforhodamine B protein
staining [18]. Experiments were repeated in triplicate and
the mean ± SE values were determined in Prism 3.0
(GraphPad Software, San Diego, CA).
Scratch wound migration and Matrigel invasion chamber 
system (MICS) assays
Assays were conducted as described by Pavey et al. [19].
Cells were seeded at 2.5 × 104 cells per well. At 0 and 24 h
after introduction of the scratch wound, cells were fixed
with methanol and stained with 1% crystal violet for 5
min at RT. Cells were washed with distilled water and
allowed to dry before being photographed, and the width
of the wound was measured. The experiment was per-
formed on three independent occasions, with triplicate
measurements each time. MICS assays were conducted
using the BD BioCoat Matrigel Invasion Chamber system
(BD Biosciences, Bedford, MA) as described by the manu-
facturer.
Results
Unsupervised hierarchical clustering of the 3,197 tran-
scripts with highest variance ( 0.5 SD) illustrated that the
normal ovarian and benign tumor samples had a similar
expression profile and were separate from a distinct clus-
ter comprising all LMP and invasive tumors (Fig. 1A).
Supervised analysis using ANOVA (with the Benjamini
and Hochberg false discovery rate (FDR) multiple testing
correction) identified 456 transcripts exhibiting signifi-
cant differences in expression between the four groups
(see Additional file 3 for the complete list of 456 tran-
scripts). Hierarchical clustering to visualize the data dem-
onstrated a similar relationship to that observed with the
unsupervised analysis, with all normal ovarian and
benign tumor samples in a separate cluster from all LMP
and invasive tumors (Fig. 1B).
Within the group of invasive tumors, four were classified
as of peritoneal rather than ovarian origin, however no
distinction between gene expression profiles of ovarian
and primary peritoneal tumors was observed by unsuper-
vised clustering or ANOVA analysis (data not shown).
Similarly, no differences in gene expression profiles were
observed between invasive tumors of different stages (I -
IV) and grades (G2 versus G3) when analyzed by unsuper-
vised clustering or supervised ANOVA with Benjamini
and Hochberg FDR multiple testing correction applied
(data not shown). Further, hierarchical clustering was not
affected by epithelial or tumor percentage content (data
not shown).
The mean age was lowest for women with normal ovarian
samples (49 years, range 41 - 57) followed by those with
LMP tumors (52 years, range 25 - 76) compared with
benign (61 years, range 46 - 69) and invasive tumors (62
years, range 25 - 80), although these differences did not
quite reach statistical significance (p = 0.08, Kruskal-Wal-
lis test). However, age had no observable effect on gene
expression profiles in unsupervised clustering analysis or
in supervised ANOVA analyses (with Benjamini and
Hochberg FDR multiple testing correction applied) and
was therefore not considered further.
The comparison of gene expression profiles of 28 invasive
and seven LMP tumors identified 20 genes with expres-
sion levels that differed significantly between the two
groups (p  < 0.01, Student's t-test with Benjamini and
Hochberg FDR) (gene list provided in Table 3). As
expected, substantially more genes exhibiting differential
expression were detected when invasive tumors were com-BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
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pared with seven benign tumors (311 genes) (Additional
file 4 details 311 transcripts) or four normal ovaries (89
genes) (Additional file 5 lists names of the 89 transcripts).
Visualization of these gene lists using a Venn diagram
demonstrated very little overlap in genes that were differ-
entially expressed between LMP and invasive tumors (20
genes) and genes that showed differential expression
when invasive tumors were compared with benign tumors
or normal ovaries (Fig. 1C). For example, of these 20
genes, only two were also identified in the normal vs inva-
sive comparison (n = 89) and one gene was also identified
in the benign vs invasive comparison. We performed Gene
Set Enrichment Analysis (GSEA) and Expression Analysis
Systematic Explorer (EASE) pathway analysis of the genes
lists obtained from all of the comparisons between tumor
and tissue groups. No significantly over-represented path-
ways were identified from either of these analyses (data
not shown).
We were interested in investigating markers associated
with the development of an invasive serous tumor and
therefore a total of six genes were selected for further anal-
ysis, including two genes from the normal ovary vs inva-
sive tumors comparison (SLPI,  GLTSCR2), two genes
from the benign vs invasive comparison (WNT7A, PDG-
FRA) and two genes from the overlap of these two analy-
Microarray analysis demonstrates differences in gene expression associated with tumor behavior Figure 1 (see previous page)
Microarray analysis demonstrates differences in gene expression associated with tumor behavior. Serous tumors 
(28 invasive, 7 low malignant potential (LMP) and 7 benign) were compared with four normal whole ovaries. (A) Unsupervised 
hierarchical clustering analysis of 3,197 transcripts exhibiting highest variance (SD  0.5) shows similar gene expression levels in 
low malignant potential and invasive tumors compared with differential expression in normal ovarian and benign tumor tissues 
(blue = normal ovaries; yellow = benign; green = low malignant potential; red = invasive). (B) Hierarchical clustering of 456 
transcripts selected from ANOVA analysis (p < 0.01, Benjamini and Hochberg FDR multiple testing correction applied, Addi-
tional file 3 for genes and details) further illustrates similar gene expression profiles exhibited by low malignant potential and 
invasive tumors as compared with normal ovaries and benign tumors. (C) Pair-wise comparisons between invasive tumors and 
low malignant potential or benign tumors (p < 0.01, Benjamini and Hochberg FDR multiple testing correction applied) identi-
fied 20 differentially expressed genes between invasive and low malignant potential tumors and 311 genes that differed in 
expression between invasive and benign tumors. (D) Differential expression as detected by microarrays is demonstrated for 
six selected genes in serous tumors exhibiting differences in behavior. Box and whisker plots depict the median (line), inter-
quartile range (box) and error bars demonstrate the full range of the data, excluding outliers and extreme values which are 
represented individually.
Table 3: Genes differentially expressed between serous invasive and low malignant potential tumors
Genbank Acc. No. Gene Description Fold difference1 p-Value
NM_003514 IGKC Immunoglobulin kappa constant 13.18 0.00484
NM_284764 FTLL1 Ferritin, light polypeptide-like 1 2.18 0.00888
NM_031157 HNRPA1 Heterogeneous nuclear ribonucleoprotein A1 0.69 0.00451
NM_017594 DIRAS2 DIRAS family, GTP-binding RAS-like 2 0.63 3.82E-05
AL122074 SLIT3 Slit homolog 3 0.58 0.00957
NM_003391 WNT2 Wingless-type MMTV integration site family member 2 0.52 0.000932
BC001356 IFI35 Interferon-induced protein 35 0.51 0.000297
NM_016140 CGI-38 Brain specific protein 0.51 0.000161
NM_078469 BCCIP BRCA2 and CDKN1A interacting protein 0.5 0.00657
NM_005014 OMD Osteomodulin 0.5 0.000953
AF070574 MGC26885 Spermatogenesis associated 2-like 0.49 0.00657
NM_013360 ZNF222 Zinc finger protein 222 0.47 0.00484
NM_024645 FLJ13842 Zinc finger, matrin type 4 0.46 0.00484
NM_004212 SLC28A2 Solute carrier family 28 0.45 0.00115
NM_017581 CHRNA9 Cholinergic receptor, nicotinic, alpha 9 0.42 0.00264
NM_006926 SFTPA2 Surfactant, pulmonary-associated protein A2 0.42 0.000253
AL365404 GPR108 G protein-coupled receptor 108 0.36 7.20E-07
NM_013941 OR10C1 Olfactory receptor, family 10, subfamily C, member 1 0.32 1.34E-05
NM_006934 SLC6A9 Solute carrier family 6, member 9 0.31 2.00E-07
NM_004720 EDG4 Endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 
4
0.25 3.91E-08
P-values were set to < 0.01 and the Benjamini and Hochberg FDR Multiple Testing Correction was applied. 1 Fold difference in normalized means of 
invasive tumors (numerator) compared with low malignant potential tumors (denominator).BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
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ses (TFPT, C6orf31) (Fig. 1C). Analyses of the microarray
data for each of the six selected genes showed significant
differences in expression between the groups (Kruskal
Wallis p < 0.05, Fig. 1D).
Differences in gene expression as judged from the micro-
array data were compared with those from real time PCR
experiments for these six genes using RNA extracted from
the initial 46 tissues. Strong correlations were found
between the microarray and real time PCR data for four of
the candidate genes, namely C6orf31, GLTSCR2, PDGFRA
and SLPI (Spearman's rank correlation coefficient  0.6, p
< 0.001). Although similar trends in WNT7A expression
were measured using microarray and real time PCR anal-
yses, a poor correlation was observed (Spearman's corre-
lation = 0.4) due to the large difference in scale of results
between the two techniques. The microarray data mini-
mized apparent differences in gene expression, possibly as
they are not optimized on a single gene basis. The real
time PCR data did not confirm the microarray analysis for
the sixth gene (TFPT).
Expression levels of the five genes confirmed by real time
PCR were further tested in a second independent set of tis-
sues comprising 46 serous tumors (4 benign, 7 LMP, 35
invasive (G2/G3)) and one normal ovary. Due to the
availability of only one normal ovary for validation stud-
ies, and the minimal differences in expression between
normal ovarian tissue and benign lesions, we combined
benign tumors with the single normal ovary for subse-
quent pair-wise comparisons. All candidate genes exam-
ined in the validation set exhibited similar trends in
expression with tumor behavior to those observed previ-
ously in the microarray tissues. Comparing invasive
tumors with grouped benign tumors and one normal
ovary, all five genes demonstrated consistent and highly
significant differences in gene expression (Kruskal Wallis
p  < 0.05, Table 4). Differential expression was also
observed between LMP tumors and benign tumors/nor-
mal ovaries for three out of five genes examined (PDG-
FRA,  SLPI,  WNT7A) and between invasive and LMP
tumors for the other two genes (C6orf31,  GLTSCR2)
(Kruskal Wallis p < 0.05).
To confirm differential expression at the protein level,
immunohistochemistry was carried out for SLPI as a reli-
able, commercially-produced antibody was available.
Evaluation of SLPI protein expression in the tissues used
for microarray analysis showed cytoplasmic protein
expression in epithelial cells in over 80% of LMP and
invasive tumors compared with detectable expression in
only one third of normal ovaries and benign tumors
(Fisher's Exact test, p < 0.05 across all tissues; Table 5, Fig.
2; Additional file 6 shows representative images of tis-
sues). SLPI staining was not observed in tumor stroma.
Higher levels of gene expression measured by microarrays
and real time PCR in LMP and invasive serous tumors
were also correlated with increased SLPI protein expres-
sion in the paraffin-embedded tissue blocks (data not
shown).
We wished to examine the effect of increasing expression
of one of the validated genes in an ovarian cancer cell line.
The largest increase observed between normal/benign and
LMP/invasive tissues in validation was in WNT7A expres-
sion. Analysis of all WNT family members interrogated by
the microarray similarly showed an increase of WNT3 and
WNT8A  expression in LMP and invasive tumors when
compared to normal or benign tissues (Table 6; Addi-
tional file 7 shows all WNT pathway and related molecule
data as taken from GSEA and EASE), possibly indicating a
more widespread activation of the WNT pathway in these
tumors. However, as the increase of WNT7A expression
was the only member of the family that was statistically
significant, we chose to focus on it. We therefore screened
a panel of 11 ovarian cancer cell lines for expression of
WNT7A  compared with immortalized human ovarian
surface epithelial cells (HOSE) (Fig. 3A). HOSE cells did
not have detectable expression of WNT7A as determined
by real time PCR, nor did 3 ovarian cancer cell lines. How-
ever, 8 of the 11 ovarian cancer cell lines showed expres-
sion of WNT7A (Fig. 3A). OVCAR-3, a cell line derived
Table 4: Validation of selected genes in an independent set of 47 tissues by real time PCR
Fold change (± SD)1 Kruskal Wallis p-Values
Genbank Acc. 
No.









NM_030651 C6orf313 0.37 ± 0.52 0.19 ± 0.49 NS, p = 0.13 p < 0.01 p < 0.05
NM_015710 GLTSCR24 0.51 ± 0.61 0.17 ± 0.22 NS, p = 0.17 p < 0.01 p < 0.01
NM_006206 PDGFRA4 0.31 ± 0.51 0.15 ± 0.22 P < 0.05 p < 0.01 NS, p = 0.13
NM_003064 SLPI 3.86 ± 1.80 5.70 ± 4.20 P < 0.05 p < 0.05 NS, p = 0.95
NM_004625 WNT7A 180.0 ± 250.0 150.0 ± 205.0 P < 0.01 p < 0.001 NS, p = 0.67
1Real time PCR results were calculated using the Pfaffl (2001) method with B2M as the reference gene. 2Low malignant potential. 3Outlier (00231) 
removed from analysis. 4Outliers (44286, 44428) removed from analysis.BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
Page 8 of 13
(page number not for citation purposes)
from ascites of a patient with adenocarcinoma of the
ovary, showed low expression of WNT7A, and was consid-
ered a good candidate for over-expression. Far greater lev-
els of WNT7A  were observed in clones derived from
independent transfections of the OVCAR-3 ovarian cancer
cell line as compared to clones containing an empty vec-
tor, as demonstrated by both real time PCR (data not
shown) and western blotting (Fig. 3B). Importantly, there
was no significant difference in growth rate of the two
OVCAR-3 control cell lines and the two OVCAR-3 clones
expressing WNT7A (data not shown).
To determine whether WNT7A  enhances tumorigenic
potential, in vitro functional studies were applied to test
the influence of WNT7A on migration and invasion capa-
bilities in OVCAR-3 cells. Scratch wound assays showed
that WNT7A over-expressing clones displayed a statisti-
cally significant increase in wound healing abilities as
compared with control clones (Fig. 3C). WNT7A over-
expressing clones also had significantly greater invasion
ability than their mock-transfected counterparts (Fig. 3D).
Discussion
The aim of the current study was to identify potential
markers of serous ovarian neoplastic transformation. We
applied gene expression profiling to evaluate the molecu-
lar relationships among serous ovarian tumors exhibiting
distinct differences in tumor behavior (LMP and invasive
tumors) and compared these with two reference groups,
benign serous ovarian tumors and normal ovarian tissue.
Unsupervised hierarchical clustering analysis demon-
strated that LMP and invasive tumors exhibited similar
gene expression profiles that were distinct from normal
ovarian and benign tumor samples. A Student's t-test with
the Benjamini and Hochberg FDR multiple testing correc-
tion applied confirmed that the gene expression profiles
of invasive and LMP tumors were similar, with only 20
genes differing (at p < 0.01) between the two tumor types.
This varied substantially from the number of genes that
differed between invasive and benign tumors (311 tran-
scripts at p < 0.01).
The finding of similar gene expression profiles in LMP and
invasive tumors was unexpected as it is widely accepted
that these tumors arise via distinct pathways [20,21]. Our
results are in agreement, however, with previous findings
in serous ovarian tumors [22,23] but contrast with other
studies [21,24-26]. In support of the current findings of
similar gene expression profiles in LMP and invasive
tumors, minimal differences in gene expression profiles
Table 5: Cytoplasmic expression of SLPI as detected by immunohistochemistry in 411 tissues evaluated by microarray analysis
Normal/benign LMP2 Invasive All tissues LMP vs Invasive
Pattern Number (%) Number (%) Number (%) p-Value3
Negative 4 (67) 1 (14) 5 (18) < 0.05 NS, p-Value = 1.0
Positive 2 (33) 6 (86) 23 (82)
1Tissue blocks were not available for five samples. 2Low malignant potential. 3Fisher's Exact Test.
Immunohistochemical detection of SLPI in serous ovarian tumors Figure 2
Immunohistochemical detection of SLPI in serous ovarian tumors. Immunohistochemistry was carried out using the 
SLPI antibody from Novocastra Laboratories Ltd (dilution 1/100) following the manufacturer's recommended protocol. (A) An 
example of an invasive serous ovarian tumor showing intense cytoplasmic staining for SLPI. (B) A low malignant potential (LMP) 
tumor displaying cytoplasmic staining. (C) A benign tumor with little or no staining for SLPI. Magnification: × 400. Bar = 50 m.
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have been reported previously in studies that compared
well-differentiated with poorly-differentiated serous inva-
sive tumors [6,26]. Thus, the evidence currently available
regarding serous ovarian cancer highlights a relatively
small number of genes that may be associated with the
acquisition of invasive potential. This is not unlike some
corresponding findings for breast cancer where similar
gene expression profiles were observed among distinct
pathological stages - premalignant atypical ductal hyper-
plasia, pre-invasive ductal carcinoma in situ and invasive
ductal carcinoma [27]. Further, our data may also suggest
that benign ovarian lesions are a distinct entity to LMP
and invasive tumors, given the differences or similarities
in gene expression profile between the tissues.
We included both normal ovarian tissue and benign
tumor samples for comparison with LMP and invasive
serous tumors. In contrast, the majority of previous stud-
ies compared ovarian cancer (various subtypes) with the
ovarian surface epithelium [2-8,24]. Contrary to our
expectations, there was much overlap between differen-
tially expressed transcripts from invasive tumor versus
'normal' tissue, regardless of whether benign tumors or
normal ovaries served as the reference. Since there were
significant differences between frankly malignant tumors
and the above-mentioned controls, these comparisons
could have minimized the differences between benign
tumors and normal ovarian tissues. It is also possible that
similar expression profiles in benign tumors and normal
ovaries may reflect the stromal content in these samples.
From the analyses of global gene expression profiles, we
focused on six genes (both novel and well-known) that
were identified as differentially expressed between either
normal ovarian tissue or benign tumors and invasive
ovarian cancer. Five of these genes were validated as hav-
ing differential expression in an independent set of serous
tumors. Increased expression of SLPI was measured in
LMP and invasive tumors at the mRNA and protein level.
These findings support previous studies showing over-
expression of SLPI in serous as well as other subtypes of
ovarian cancer [28-31].
Decreased expression of C6orf31, PDGFRA and GLTSCR2
was measured in LMP and invasive tumors compared with
high mRNA levels in benign tumors and normal ovarian
tissues. To our knowledge, this is the first report of the
potential involvement of C6orf31  (located on chromo-
some 6p21) in cancer development. PDGFRA encodes a
cell surface tyrosine kinase receptor for members of the
platelet-derived growth factor family. Similar observa-
tions of decreased PDGFRA expression in invasive serous
tumors compared with benign tumors or normal ovaries
have been reported in previous microarray studies
[22,32]. In contrast, PDGFRA was also identified as over-
expressed in a poor prognosis gene expression signature in
Table 6: Expression profiling data of WNT family members
Ratios





NM_005430 WNT1 1.02 ± 0.16 1.24 ± 0.22 1.03 ± 0.23 0.94 ± 0.28 0.92 0.76 0.91
NM_003391 WNT2 0.94 ± 0.31 1.17 ± 0.20 1.83 ± 0.44 0.94 ± 0.24 1.00 0.80 0.52*
NM_024494 WNT2B 1.46 ± 0.74 1.10 ± 0.68 1.03 ± 0.37 0.90 ± 0.38 0.61 0.82 0.87
NM_030753 WNT3 0.01 ± 0.01 0.08 ± 0.22 2.28 ± 5.64 1.32 ± 2.64 529.7 15.9 0.58
NM_033131 WNT3A 1.07 ± 0.21 1.20 ± 0.35 1.01 ± 0.10 0.95 ± 0.23 0.89 0.79 0.94
AB062766 WNT4 0.97 ± 0.13 1.10 ± 0.24 0.94 ± 0.15 0.98 ± 0.20 1.01 0.89 1.04
NM_030761 WNT4 1.00 ± 0.08 1.14 ± 0.16 1.10 ± 0.26 0.98 ± 0.20 0.99 0.86 0.89
NM_003392 WNT5A 0.91 ± 0.62 1.36 ± 0.44 1.10 ± 0.33 0.79 ± 0.35 0.87 0.58 0.72
NM_032642 WNT5B 1.13 ± 0.22 0.91 ± 0.16 0.96 ± 0.23 1.05 ± 0.19 0.93 1.15 1.09
NM_006522 WNT6 0.87 ± 0.57 1.16 ± 0.16 0.93 ± 0.11 1.05 ± 0.19 1.21 0.91 1.13
NM_004625 WNT7A 0.61 ± 0.19 0.60 ± 0.13 0.71 ± 0.28 1.26 ± 0.47 2.05 2.09* 1.76
NM_031933 WNT8A 0.52 ± 0.69 0.09 ± 0.23 2.08 ± 3.51 2.02 ± 4.72 3.85 22.9 0.97
NM_003393 WNT8B 1.27 ± 0.40 1.29 ± 0.33 1.55 ± 1.44 1.03 ± 0.43 0.81 0.80 0.66
NM_003395 WNT9A 1.14 ± 0.13 1.06 ± 0.20 1.09 ± 0.34 0.99 ± 0.31 0.87 0.94 0.91
NM_003396 WNT9B 1.00 ± 0.12 0.92 ± 0.49 0.99 ± 0.35 1.15 ± 0.71 1.15 1.25 1.16
NM_025216 WNT10A 1.23 ± 0.17 1.19 ± 0.28 1.02 ± 0.19 0.95 ± 0.20 0.78 0.80 0.93
NM_003394 WNT10B 0.54 ± 0.62 0.65 ± 0.63 1.04 ± 1.17 0.73 ± 0.69 1.35 1.12 0.70
NM_004626 WNT11 0.91 ± 0.19 1.00 ± 0.20 0.96 ± 0.10 0.97 ± 0.27 1.06 0.97 1.00
NM_057168 WNT16 1.01 ± 0.38 0.74 ± 0.36 1.22 ± 0.38 1.02 ± 0.41 1.01 1.39 0.84
* p < 0.01, Benjamini and Hochberg FDR multiple testing correction applied.BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
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ovarian cancer and it was suggested that PDGFRA could be
associated with the occurrence of an epithelial/mesenchy-
mal transition [33].
A trend of decreasing GLTSCR2 expression with increas-
ingly aggressive tumor behavior was observed in the cur-
rent study. Previous results demonstrated that down-
regulation of GLTSCR2 directly enhanced degradation of
wild-type PTEN in breast cancer (MCF7) cells [34]. Thus it
was hypothesized that dysfunctional GLTSCR2 could lead
to activation of PI3K signaling via rapid turnover of PTEN
[35]. In serous ovarian cancer, amplification of multiple
components of the PI3K pathway have been reported
[36,37] although PTEN mutation has rarely been identi-
fied [38].
The finding of increased WNT expression in LMP and
invasive tumors, in particular WNT7A,  WNT3  and
WNT8A, was of interest because it has been hypothesized
that aberrant Wnt activation is associated with the initia-
tion and growth of cancer in tissues since Wnt signaling is
normally involved in growth and patterning [39]. Wnt
activation, specifically Wnt7a, is required for the develop-
ment of the female reproductive tract from the Mullerian
ducts into the oviduct (fallopian tubes), uterus, cervix and
upper vagina during murine embryogenesis [40,41].
WNT7A has previously been shown to play a role in the
migration of normal cornea cells in response to wounding
[42]. The function of WNT7A has not previously been
examined in ovarian cancer. In the current study, overex-
pression of WNT7A  in the ovarian cancer cell line
OVCAR-3 resulted in increased cell migration and inva-
Figure 3




























































































































a Over-expression of WNT7A promotes in vitro migration and  invasion and in OVCAR-3 ovarian cancer cells Figure 3
Over-expression of WNT7A promotes in vitro migra-
tion and invasion and in OVCAR-3 ovarian cancer 
cells. (A) Quantitative real-time reverse transcription-PCR 
detection of WNT7A mRNA in immortalized human ovarian 
surface epithelial cells (HOSE) and 11 ovarian cancer cell 
lines. All data was normalized to B2M expression. Data rep-
resents duplicate assays in duplicate experiments. (B) West-
ern blot analysis confirmed higher levels of WNT7A in 
transfected clones (Wnt-C5 and Wnt-P2) as compared to 
the control clones (Con-P1 and Con-P2). (C) Migration abil-
ity was measured using an in vitro scratch wound healing 
assay. Above, photographs of wound regions taken immedi-
ately after or 24 hours after scratch was performed. Below, 
significant difference was confirmed between the WNT7A 
transfected clones and the mock clones upon measurement 
of the scratch wounds. (D) Invasion activity was measured in 
vitro using MICS invasion chambers; bars, SD. A dramatic 
increase in the number of invading cells was observed in both 
of the WNT7A transfected clones relative to the mock 
clones. bars, SD. *, p < 0.05; **, p < 0.02; ***, p < 0.01.BMC Cancer 2009, 9:378 http://www.biomedcentral.com/1471-2407/9/378
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sive capacity. The data presented here is limited by the use
of a single cell line. Further analyses of additional ovarian
cancer cell lines with either overexpression or ablation of
WNT7A would be needed to precisely identify its role in
ovarian cancer progression. Likewise, the role of WNT3
and  WNT8A  in ovarian cancer needs to be further
addressed. The data presented here may suggest a wide-
spread activation of the WNT pathway in LMP and inva-
sive tumors, although initial pathway analysis did not
indicate this to be the case. A preliminary study reported
possible activation of canonical Wnt signaling in high
grade serous tumors [43] but another study did not sup-
port this suggestion [44].
Conclusion
This study showed that an unexpectedly small number of
genes distinguished serous LMP and invasive tumors. Fur-
ther studies of these genes may highlight those with an
important role in the acquisition of invasive potential and
could lead to the development of improved therapies for
ovarian cancer. Molecular profiling of serous ovarian
tumors exhibiting differences in behavior identified sev-
eral genes potentially involved in neoplastic transforma-
tion.  In vitro functional studies of one of these genes
suggested a role for WNT7A in promoting migration and
invasion in ovarian cancer cells. Further understanding of
how serous ovarian tumors develop will contribute
towards an improvement in strategies for the prevention
and early detection of ovarian cancer.
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